Clinical Trials

Latest Headlines

Latest Headlines

AstraZeneca gets some good news for its late-stage gout therapy

AstraZeneca's gout drug lesinurad hit its primary endpoint in a Phase III trial, the company said, a welcome turn for one of the drugmaker's top prospects amid a thin slate of late-stage therapies.

Lundbeck teams with Otsuka on Alzheimer's vaccine development

The vaccine, which is designed to work through early inhibition of amyloid beta depositions, is due to enter Phase I trials next year.

ImmunoCellular tanks after cancer vaccine flops on key endpoint in PhII

ImmunoCellular Therapeutics put out the word Wednesday afternoon that its dendritic cell-based vaccine for brain cancer flunked the key overall survival test in Phase II, news that swiftly wiped out more than half of the small biotech's market cap as shares instantly cratered.

Oxygen Bio taps Duke's in-house CRO to run Phase III for its cardio drug

Duke University leads the way among schools with on-campus CROs, and now Oxygen Biotherapeutics has entrusted the institution with handling late-stage studies of its promising heart drug.

Avanir hits the skids after its pain drug flunks a mid-stage study

Avanir Pharmaceuticals watched its shares tank more than 20% after its lead pain candidate failed to outdo a placebo in a Phase II study of patients with multiple sclerosis.

CytRx soars on positive results for PhIIb sarcoma drug study

After months of building investors' expectations for its Phase IIb study for the cancer conjugate aldoxorubicin as a potential first-line treatment for soft tissue sarcoma, the small-cap biotech CytRx today said that it found an 80% to 100% improvement in the progression-free survival rate for its new-and-improved chemotherapy drug compared to the original chemo, sending its shares up more than 70% in premarket trading.

Genocea begins a PhI trial of its rival to Pfizer's Prevnar

The huge sales generated by Prevnar 13 mean Pfizer appears to have the pneumococcal vaccine sector sewn up, but Genocea Biosciences sees an opportunity to disrupt the monopoly. This week, the biotech began a Phase I clinical trial of the vaccine it thinks can unseat Prevnar.

AbbVie's second PhIII hep C study confirms cocktail's promise

AbbVie is rolling out its second snapshot of promising Phase III data for its hepatitis C cocktail, demonstrating that the vast majority of patients taking the therapy were cleared of the virus after 12 weeks of dosing.

Merck pushes Alzheimer's drug into PhIII trials after clearing a safety hurdle

The pharma giant is recruiting new patients while expanding the program with a new Phase III study for early-stage patients--without changing the dosing regimen.

Pfizer's unlocked trial data could be a boon to CROs

Pfizer has joined the list of Big Pharmas caving to public pressure and opening up their data vaults, and that could mean a valuable trove of study results for CROs plotting new trials--assuming the drugmaker feels like sharing.